Boston Scientific recalls vascular grafts
Mon Jun 27, 2005 05:13 PM ET
NEW YORK, June 27 (Reuters) - Boston Scientific Corp. (BSX.N: Quote, Profile, Research) on Monday said it has recalled all of its Hemashield Vantage vascular grafts made in the last two years because they might fray or tear during suturing.
The company said it has learned of three reported post-operative failures of the devices.
The total number of the grafts shipped but not yet implanted is about 500, Boston Scientific said, adding that it was working with the U.S. Food and Drug Administration on the recall and notifying officials in other countries.
� Reuters 2005. All Rights Reserved.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq and all other quotes delayed by at least 15 minutes. Reuters does not endorse the views or opinions given by any third party content provider.
Printer Friendly | Email Article | Reprints
Court rules against file-trading networks
Oil hits record near $61 on robust demand
Lear to trim up to 7,700 jobs
Ads by GoogleWhat's This?Buy Stocks for $4.
No Account or Investment Minimums.No Inactivity Fees.
Models and Money;Stocks Never Looked This Good!
Products and Information relatedto Stocks
Reuters.com Help & Info. | Contact Us | Feedback | Advertise | Disclaimer | Copyright | Privacy | Corrections | Partner Newspapers
About Us | Products & Services | Customer Zone | Careers
A friend of mine knows a friend who's cousin's great grandfather had the flu and took aspirin for the 104 fever he had. Now he is dead. These aspirin people need to clean up their quality control. People depend on these drugs to work.
bla, bla, bla, bla
My friend told me about his cousin who went to the hospital with some minor chest pain, next thing he knew he was scheduled for surgery to be fitted with a Taxus stent. Now he is dead. They really need to clean up their quality control.
People depend on these products to work.
Nobody has to lie about bad news on this stock, thats all there is. Every day another recall or something. Just pick any news from BSX its bad.
Boston Scientific needs a transfusion
Wednesday November 12, 11:01 pm ET
Q: When should I give up on my shares of Boston Scientific (BSX)?
A: Boston Scientific, a maker of devices called stents that hold open blocked arteries, has been an absolute disaster for investors this year.
Through Wednesday, the stock has lost almost a third of its value. And it hasn't been just a few bad days on Wall Street. We're talking about a slow and steady decline.
Investors have many reasons to be negative. Most recently, on Oct. 14, the company disappointed investors by reporting it is losing market share in the stent business and it reported a $269 million loss in the third quarter. Much of the loss was due to a $598 million legal settlement with a former supplier. But it goes beyond that: Sales are slowing for one of its stents that was a big earnings driver last year.
And it doesn't get any better looking ahead. The company slashed its outlook for this year's earnings. Its top-selling stent, Taxus, is being hurt by its only real rival: Johnson & Johson's Cypher. The number of rivals to Taxus will only increase. If the company is having trouble executing with just one rival, imagine how tough things can get with more.
That puts Boston Scientific in a tough spot.
There seems to be a stent surplus in hospitals, this inventory glut could possibly take years to work through, as hospitals seem to be overstocked with a buildup of stents. This huge surplus could be bad, also BSX may have to have a writeoff for their unused inventory, or mark down prices to next to nothing with so many competitors in the field.
That may be why insiders are selling so much at the lows, also why the charts are indicating a sell signal. Seems like they are losing a lot of employees, either due to greener pastures, or they are possibly just laying them off because they know sales are declining so they don't need as many support people.
At a recent cardiology meeting, Boston Scientific ( BSX ) startled the audience with ghastly photos of a coronary device that showed its drug coating coming off in flakes. "I knew this would cause trouble," said Boston Scientific's chief operating officer, Paul LaViolette, "but there's no such thing as bad p.r."
Last week, Boston Scientific did it again, with its startling offer to buy Guidant ( GDT ) for $72 a share, right after J&J had forced Guidant -- under fire from problems with some of its medical devices -- to accept 63 bucks, instead of the $76 price offered by J&J last year.
Nudell's discounted-cash-flow model for the combination leaves him with the tepid conclusion that Boston Scientific would get only a breakeven return for the $20 billion it spends on Guidant (net of Guidant's current cash).
He believes that stent sales have peaked in 2005 and that health insurers like Medicare will nudge doctors to become more selective in prescribing implanted defibrillators, after studies showing that up to 30% of defibrillator recipients don't need them and that a majority have hearts too damaged to enjoy a meaningful benefit. "I'm a stick in the mud," Nudell admits.
Wow I hope theres no more lawsuits.
Looks like the FDA is tired of giving warning letters and may finally take some action.
Second FDA warning for Boston Scientific over Vaxcel line
Wednesday August 17, 11:32 am ET
Following a second warning from the U.S. Food and Drug Administration about quality controls at Boston Scientific Corp.'s manufacturing plant in Glens Falls
Boston Scientific shares fall on 3rd FDA warning
Tuesday August 23, 5:01 pm ET
A spokesman for Boston Scientific Corp. on Tuesday said the company had already identified the shipping mistakes cited in a warning by the U.S. Food and Drug Administration.
In several of the shipments, which involved eighteen Taxus Express stents that failed to meet quality tests,
lawsuits, stents killing patients, FDA recalls, insider selling,inreasing competition with superior products, growing debt, defective products,recalls, along with a superbearish chart?
U.S. govt warns against Boston Scientific device
Tue Oct 18, 2005 12:10 AM ET
NEW YORK, Oct 17 (Reuters) - The U.S. Food and Drug Administration told doctors on Monday to stop using Enteryx, a device used to treat acid-reflux disease that Boston Scientific Corp. (BSX.N: Quote, Profile, Research) recalled last month.
The FDA said doctors should immediately stop injecting Enteryx, due to serious adverse effects, including death, occurring in patients treated with the liquid chemical polymer used for gastroesophageal reflux disease.
Enteryx is intended to be injected into the lower esophageal sphincter where it polymerizes into a spongy material that cannot be removed, the FDA said in a notice on its Web site (www.fda.gov).
Boston Scientific issued a recall of its Enteryx procedure kits and its Enteryx injector single packs on Sept. 23, the FDA said.
While some problems with the device related to how it was injected, not all injuries were the result of user technique, the FDA said.
It said one reported death was due to injection of Enteryx into the wall of the aorta and cited numerous cases of possible inflammatory reactions occurring even when proper procedures were followed.
A representative of Boston Scientific was not immediately available for comment.
If...if....if...post entirely of speculation. I can do the same thing:
IF BSX were to capture 99% of the DES market; and
IF BSX were to sell each Taxus stent for $250,000; and
IF Bill Gates were to donate his share of Microsoft to BSX for their humanitarian works; and
IF a giant meteorite made of solid platinum were to land on BSX campus in Minnestoa;
Then I predict this stock is undervalued. BUY NOW! It could happen!!
You say.."Unless there is a buyout and
that is not going to happen or if it does happen I can
guarentee you it will be for less than $20,"
I'd like to know how that guarentee of yours works. If BSX is boughtout for more than $20 what are you going to give me?
Or do you just spot off most anything, naughty? Stupid stuff like "They have to pay interest on the ever increasing debt they have, they have to pay employees,they have bills," Please tell us all what company you invest in where there are no bills and the employees work for free. I think you are Maximus Stupidus.